Skip to main content

Table 1 Characteristics of patients

From: Challenging clinical cases in HCV infection

Case #

Gender

Age

Hemoglobinopaty

Year of HCV diagnosis

HCV genotype

HCV-RNA (IU/l)

Hemoglobin (g/dl)

ALT (IU/l)

Metavir score

HCV therapy

Duration of therapy (weeks)

Response

3

F

35

Thalassemia mayor

1990

2a

Baseline

3,590,000

Baseline

10.1

Baseline

112

F2 (estimated through liver elastography)

Peg-Interferon 100 µg per week

24

Responder

      

Week 4

nd

Week 4

 

Week 4

61

    
      

Week 12

nd

Week 12

 

Week 12

53

    
      

Week 24

nd

Week 24

 

Week 24

Normal

 

Ribavirin 800 mg/day

  
      

End of treatment

nd

End of treatment

 

End of treatment

Normal

    
      

Follow up

nd

Follow up

 

Follow up

Normal

    

4

M

38

Thalassemia mayor

1991

4

Baseline

18,900,000

Baseline

8.9

Baseline

 

F2 (estimated through liver elastography)

Peg-Interferon 180 µg per week

24

Non responder

      

Week 4

3810

Week 4

 

Week 4

     
      

Week 12

3830

Week 12

 

Week 12

     
      

Week 24

21,900

Week 24

 

Week 24

  

Ribavirin 800 mg/day

  
      

End of treatment

21,900

End of treatment

 

End of treatment

     
      

Follow up

3,350,000

Follow up

 

Follow up

     

5

M

31

Drepanocytosis

1990

1b

Baseline

745,000

Baseline

8.3

Baseline

Twofold the normal

F2

Peg-Interferon 100 µg per week

72

Responder

      

Week 4

not available

Week 4

 

Week 4

     
      

Week 12

34470

Week 12

 

Week 12

     
      

Week 24

nd

Week 24

 

Week 24

  

Ribavirin 800 mg/day

  
      

End of treatment

nd

End of treatment

 

End of treatment

     
      

Follow up

nd

Follow up

 

Follow up

     

6

F

42

Thalassemia mayor

1991

2a

Baseline

3,430,000

Baseline

8.9

Baseline

106

F2 (estimated through liver elastography)

Peg-Interferon 100 µg per week

24

Relapser

      

Week 4

nd

Week 4

 

Week 4

     
      

Week 12

nd

Week 12

 

Week 12

     
      

Week 24

nd

Week 24

 

Week 24

  

Ribavirin 800 mg/day

  
      

End of treatment

nd

End of treatment

 

End of treatment

     
      

Follow up

1,360,000

Follow up

 

Follow up